IMDX Revenue Soars 638% Amidst Continued Losses, Strategic Rebrand

TL;DR

**IMDX is burning cash despite massive revenue growth, but new Medicare reimbursement for GraftAssureCore could be a game-changer if they can scale sales.**

AI Summary

Insight Molecular Diagnostics Inc. (IMDX) reported a significant increase in net revenue for the nine months ended September 30, 2025, reaching $2.916 million, up from $395,000 in the same period of 2024, representing a 638% increase. Despite this revenue growth, the company posted a net loss of $27.267 million for the nine-month period, nearly identical to the $27.152 million loss in 2024. Operating expenses rose to $29.491 million from $27.559 million year-over-year, driven by increased research and development expenses of $10.071 million (up from $7.582 million) and sales and marketing expenses of $4.052 million (up from $2.742 million). The company's cash and cash equivalents significantly increased to $18.692 million as of September 30, 2025, from $8.636 million at December 31, 2024, primarily due to $29.143 million in proceeds from the sale of common shares. IMDX rebranded its VitaGraft assay to GraftAssureCore and GraftAssureIQ, and received a positive Medicare reimbursement decision in May 2025, boosting the rate to $2,753 per result for GraftAssureCore. The company also moved its headquarters to Nashville, Tennessee, and changed its name from Oncocyte Corporation in June 2025.

Why It Matters

For investors, IMDX's substantial revenue growth, particularly from its GraftAssureCore product with a boosted Medicare reimbursement rate of $2,753, signals potential for future profitability in the competitive molecular diagnostics market. The strategic rebranding and headquarters move to Nashville could enhance its market position and operational efficiency. However, persistent operating losses and negative cash flows from operations, alongside a significant increase in common shares outstanding (from 17,453 to 28,625 thousand shares), indicate ongoing dilution risk and a need for sustained capital raises. The company's focus on developing DetermaIO for oncology therapy selection positions it in a high-growth segment, but successful commercialization is critical for long-term viability against established players.

Risk Assessment

Risk Level: high — IMDX has an accumulated deficit of $377.8 million as of September 30, 2025, and expects to continue incurring operating losses and negative operating cash flows for the foreseeable future. The company's total liabilities of $53.133 million significantly exceed its total assets of $43.937 million, resulting in a shareholders' deficit of $9.196 million, indicating a precarious financial position.

Analyst Insight

Investors should monitor IMDX's ability to convert its increased Medicare reimbursement rate for GraftAssureCore into substantial, sustained revenue growth and improved gross margins. Watch for signs of reduced operating losses and positive cash flow from operations in subsequent quarters, as continued reliance on equity financing will lead to further shareholder dilution.

Financial Highlights

debt To Equity

N/A

revenue

$2.916M

operating Margin

N/A

total Assets

$43.937M

total Debt

$53.133M

net Income

-$27.267M

eps

N/A

gross Margin

61.8%

cash Position

$18.692M

revenue Growth

+638%

Revenue Breakdown

Key Numbers

• $2.916M — Net revenue for nine months ended Sept 30, 2025 (Increased from $395,000 in 2024, a 638% increase.)
• $27.267M — Net loss for nine months ended Sept 30, 2025 (Consistent with $27.152 million loss in 2024, indicating continued unprofitability.)
• $18.692M — Cash and cash equivalents as of Sept 30, 2025 (Increased from $8.636 million at Dec 31, 2024, primarily due to equity financing.)
• $2,753 — Medicare reimbursement rate per result for GraftAssureCore (Boosted in May 2025, improving potential revenue per test.)
• $377.8M — Accumulated deficit as of Sept 30, 2025 (Highlights significant historical losses and ongoing financial challenges.)
• 28,625 — Shares of common stock outstanding (in thousands) as of Sept 30, 2025 (Increased from 17,453 thousand shares at Dec 31, 2024, indicating significant dilution.)
• $10.071M — Research and development expenses for nine months ended Sept 30, 2025 (Increased from $7.582 million in 2024, reflecting ongoing investment in product development.)
• $9.196M — Total shareholders' deficit as of Sept 30, 2025 (Indicates liabilities exceed assets, a negative equity position.)

Key Players & Entities

• Insight Molecular Diagnostics Inc. (company) — registrant
• IMDX (company) — trading symbol
• Nasdaq Stock Market LLC (regulator) — exchange where securities are registered
• Oncocyte Corporation (company) — former name of IMDX
• Nashville, Tennessee (location) — new headquarters and CLIA-certified lab location
• GraftAssureCore (company) — rebranded lab developed test
• GraftAssureIQ (company) — rebranded kitted research-use-only assay
• DetermaIO (company) — oncology diagnostic test in development
• Bio-Rad Laboratories, Inc. (company) — collaboration partner
• Centers for Medicare and Medicaid Services (regulator) — payer for diagnostic tests

FAQ

Risk Factors

• Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $27.267 million for the nine months ended September 30, 2025, which is nearly identical to the $27.152 million loss in the prior year. The accumulated deficit stands at $377.8 million as of September 30, 2025, indicating a substantial history of unprofitability and ongoing financial challenges.
• Significant Shareholder Dilution [medium — financial]: The number of common shares outstanding increased from 17,453 thousand at December 31, 2024, to 28,625 thousand at September 30, 2025. This represents a substantial dilution of approximately 64%, primarily due to proceeds from the sale of common shares totaling $29.143 million.
• Increasing Operating Expenses [medium — operational]: Operating expenses rose to $29.491 million for the nine months ended September 30, 2025, from $27.559 million in the same period of 2024. This increase is largely attributable to higher research and development expenses ($10.071 million vs. $7.582 million) and sales and marketing expenses ($4.052 million vs. $2.742 million).
• Reliance on Reimbursement Decisions [medium — regulatory]: The company's revenue is significantly influenced by reimbursement decisions, such as the positive Medicare decision for GraftAssureCore. Changes or challenges in obtaining or maintaining favorable reimbursement rates could materially impact future revenue and profitability.
• Product Rebranding and Market Adoption [medium — market]: The rebranding of the VitaGraft assay to GraftAssureCore and GraftAssureIQ, along with the positive Medicare reimbursement, are key drivers of recent revenue growth. However, the success of these products will depend on market adoption and competitive pressures.

Industry Context

The molecular diagnostics industry is characterized by rapid technological advancements and a growing demand for personalized medicine. Companies in this space often face significant R&D costs and rely heavily on regulatory approvals and reimbursement policies. The competitive landscape includes established players and emerging innovators, with a focus on improving diagnostic accuracy and expanding test menus for various diseases.

Regulatory Implications

IMDX's reliance on Medicare reimbursement for its GraftAssureCore product presents a significant regulatory risk. Changes in reimbursement policies, coverage decisions, or pricing by government and private payers could materially impact revenue. Furthermore, ongoing compliance with FDA regulations for diagnostic tests is critical for market access and continued operation.

What Investors Should Do

1. Monitor R&D and Sales & Marketing Spend
2. Analyze Cash Burn Rate and Future Financing Needs
3. Evaluate Reimbursement Landscape and Payer Mix
4. Assess Progress on Product Adoption and Market Penetration

Key Dates

• 2025-05-01: Positive Medicare reimbursement decision for GraftAssureCore — Secured a reimbursement rate of $2,753 per result, significantly boosting the revenue potential for a key product.
• 2025-06-01: Company name change to Insight Molecular Diagnostics Inc. — Reflects a strategic shift or rebranding, moving away from the Oncocyte Corporation identity.
• 2025-09-30: End of the nine-month period for reporting — Period during which significant revenue growth and substantial net loss were reported, alongside a major increase in cash from equity financing.
• 2024-12-31: End of the fiscal year 2024 — Baseline for comparison of cash position and share count at the beginning of the reporting period.

Glossary

Accumulated deficit

The cumulative net losses of a company over its lifetime that have not been offset by net income. (Indicates the company has historically incurred more expenses than revenues, standing at $377.8 million as of September 30, 2025.)

Shareholders' deficit

A negative equity position where a company's liabilities exceed its assets. (IMDX has a shareholders' deficit of $9.196 million as of September 30, 2025, highlighting its negative net worth.)

Contingent consideration liabilities

Obligations to pay additional amounts in the future, typically related to acquisitions, contingent on certain future events or performance targets. (These liabilities increased significantly, totaling $43.944 million non-current and $1.056 million current as of September 30, 2025, suggesting potential future cash outflows.)

Amortization of acquired intangibles

The systematic expensing of the cost of intangible assets (like patents or acquired technology) over their useful lives. (This cost was $7 million for the nine months ended September 30, 2025, contributing to the cost of revenues.)

Right-of-use and financing lease assets/liabilities

Assets and liabilities recognized under lease accounting standards for leases longer than 12 months, representing the right to use an asset and the obligation to make lease payments. (These represent significant long-term obligations and assets on the balance sheet, with current portions of $1.598 million and non-current of $1.529 million for liabilities.)

Year-Over-Year Comparison

Insight Molecular Diagnostics Inc. has demonstrated exceptional revenue growth, increasing net revenue by 638% to $2.916 million for the nine months ended September 30, 2025, compared to the same period in 2024. However, this growth has not translated to profitability, with the net loss remaining substantial at $27.267 million, largely consistent with the prior year's $27.152 million loss. Operating expenses have also risen, particularly in R&D and sales/marketing. The company's cash position has significantly improved due to equity financing, but this has come with considerable shareholder dilution. New risks related to contingent consideration liabilities have emerged, while the accumulated deficit continues to grow.

Filing Documents

• imdx-20250930.htm (10-Q) — 3601KB
• imdx-ex31_1.htm (EX-31.1) — 14KB
• imdx-ex31_2.htm (EX-31.2) — 14KB
• imdx-ex32_1.htm (EX-32.1) — 11KB
• 0001193125-25-274266.txt ( ) — 14721KB
• imdx-20250930.xsd (EX-101.SCH) — 1693KB
• imdx-20250930_htm.xml (XML) — 3201KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 CONDENSED CONSOLIDATED BALANCE SHEETS 3 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 4 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 5 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS' EQUITY (DEFICIT) 6 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 8 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 45

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 57

Controls and Procedures

Item 4. Controls and Procedures 57

- OTHER INFORMATION

PART II - OTHER INFORMATION 59

Legal Proceedings

Item 1. Legal Proceedings 59

Risk Factors

Item 1A. Risk Factors 59

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 61

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 61

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 61

Other Information

Item 5. Other Information 61

Exhibits

Item 6. Exhibits 62

SIGNATURES

SIGNATURES 63 1 Table of Contents CAUTIONARY NO TE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this Quarterly Report on Form 10-Q (this "Report") are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Insight Molecular Diagnostics Inc., or iMDx (f/k/a Oncocyte Corporation), along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Any statements that are not historical fact (including, but not limited to statements that contain words such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would" or similar expressions or the negative of such terms) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of iMDx, particularly those mentioned in this Report under Risk Factors and those Risk Factors in Part I, Item 1A. of our most recent Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission ("SEC"). Except as required by law, iMDx undertakes no obligation to update any forward-looking statements to reflect events or circumstances afte

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. INSIGHT MOLECULAR DIAGNOSTICS INC. CONDENSED CONS OLIDATED BALANCE SHEETS (In thousands) September 30, 2025 December 31, 2024 (Unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 18,692 $ 8,636 Accounts receivable, net of allowance for credit losses of $ 3 and $ 16 , respectively 258 1,613 Inventories 471 410 Deferred financing costs — 279 Restricted cash, current 729 — Prepaid expenses and other current assets 1,239 821 Total current assets 21,389 11,759 NONCURRENT ASSETS Right-of-use and financing lease assets, net 2,340 2,757 Machinery and equipment, net, and construction in progress 4,147 3,567 Intangible assets, net 14,600 14,607 Restricted cash, noncurrent 789 1,700 Other noncurrent assets 672 691 TOTAL ASSETS $ 43,937 $ 35,081 LIABILITIES AND SHAREHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable $ 1,056 $ 2,279 Accrued compensation 2,228 1,939 Accrued royalties 1,120 1,116 Accrued expenses and other current liabilities 602 418 Right-of-use and financing lease liabilities, current 1,598 1,295 Contingent consideration liabilities, current 1,056 228 Total current liabilities 7,660 7,275 NONCURRENT LIABILITIES Right-of-use and financing lease liabilities, noncurrent 1,529 2,369 Contingent consideration liabilities, noncurrent 43,944 37,711 TOTAL LIABILITIES 53,133 47,355 Commitments and contingencies (Note 6) SHAREHOLDERS' DEFICIT Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding — — Common stock, no par value, 230,000 shares authorized; 28,625 and 17,453 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 368,524 338,244 Accumulated other comprehensive income 86 21 Accumulated deficit ( 377,806 ) ( 350,539 ) Total shareholders' deficit ( 9

View Full Filing

View this 10-Q filing on SEC EDGAR